Deal, United Kingdom

John K Stubbs


Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 159(Granted Patents)


Location History:

  • Deal, EN (1976 - 1978)
  • Nordelph, GB (1985)
  • Deal, GB (1978 - 1987)

Company Filing History:


Years Active: 1976-1987

Loading Chart...
21 patents (USPTO):Explore Patents

Title: **The Innovative Journey of John K. Stubbs in Pharmaceutical Advancements**

Introduction

John K. Stubbs, located in Deal, GB, is a prolific inventor with an impressive portfolio of 21 patents to his name. His work primarily focuses on developing innovative anti-ischaemic agents, contributing significantly to the pharmaceutical industry and advancing medical science.

Latest Patents

Among his latest patents, Stubbs has pioneered two key inventions: the formulation of Dihydropyridines, which are recognized for their therapeutic potential as anti-ischaemic agents. The first patent details dihydropyridine compounds of the formula where R is aryl or heteroaryl, with R₁ and R₂ representing C₁-C₄ alkyl or 2-methoxyethyl. The compound's specific structure emphasizes its innovative approach to treating ischaemic conditions. The second patent explores 2-pyrimidylaminoalkoxymethyl-6-methyl-3,5-bis-dihydropyridine, further expanding on the versatility of such compounds, detailing a similar configuration with unique substituents that enhance its pharmacological profile.

Career Highlights

John K. Stubbs's career is marked by his contributions to Pfizer Corporation, a leading name in the pharmaceutical sector. His role at Pfizer has allowed him to merge his creativity with scientific research, leading to the successful development of groundbreaking medical treatments. Stubbs' dedication to research and his innovative spirit have resulted in numerous patents that showcase his expertise and commitment to improving health outcomes.

Collaborations

Throughout his career, Stubbs has collaborated with notable colleagues, including Simon F. Campbell and Peter E. Cross. These partnerships have fostered an environment of shared ideas and collective innovation, further driving advancements in drug development and research. Together, they have worked on various projects that highlight the potential of new therapeutic agents, significantly impacting patient care and treatment methods.

Conclusion

John K. Stubbs stands out as a vital contributor to the field of pharmacology, with his extensive patent portfolio reflecting his innovative mindset and scientific acumen. His work at Pfizer Corporation and collaborations with other distinguished professionals underscore his commitment to advancing medical technology. As the landscape of pharmaceuticals continues to evolve, Stubbs’ contributions to the development of anti-ischaemic agents will undoubtedly leave a lasting legacy in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…